Navigation Links
Mylan Receives Approval for Fludarabine Phosphate Injection, USP
Date:10/4/2010

PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).  

Fludarabine Phosphate Injection USP, 25 mg/mL had U.S. sales of approximately $15 million for the 12 months ending June 30, 2010, according to IMS Health.

Bioniche Pharma is part of Mylan Institutional, a newly created platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.

Currently, Mylan has 150 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Wellbutrin XL® Tablets
2. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
3. Mylan Receives Approval for Generic Version of Prograf® Capsules
4. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
5. Mylan Announces Completion of Add-On Offering of Senior Notes
6. Mylan Announces Pricing of Add-On Offering of Senior Notes
7. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
8. Mylan Announces Settlement Agreement for Namenda®
9. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
10. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
11. Mylan Receives Approval for Nabumetone Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , 8. Dezember 2016 Mederi Therapeutics Inc . hat die ... nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in China ... ... Live Stretta procedure performed ... Liu, Director of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dignitana, a world leader in medical scalp-cooling technology, has ... the award-winning, patented Boa® system, to produce an adaptive, ... cooling system. DigniCap® was cleared by the U.S. Food ... first medical scalp cooling device to receive FDA clearance. ... patented tight-fitting silicone cooling cap that is placed directly ...
(Date:12/8/2016)... Ariz., Dec. 8, 2016  Economic growth in the ... purchasing and supply management executives in their December 2016 ... the economic recovery that began in mid-2009, as indicated ... Business ® . The manufacturing sector is optimistic ... in 16 manufacturing industries, and the non-manufacturing sector indicates ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
(Date:12/8/2016)... OH (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Hamilton County, is embarking ... rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected ...
(Date:12/8/2016)... ... 08, 2016 , ... Coffey Agencies, a locally owned and ... in the northern Alabama and Georgia regions, is embarking on a charity drive ... has built a network of support and education facilities to develop and provide ...
Breaking Medicine News(10 mins):